Digestive Diseases and Sciences

, Volume 55, Issue 3, pp 675–683 | Cite as

Comparison of the Effect of Azithromycin Versus Erythromycin on Antroduodenal Pressure Profiles of Patients with Chronic Functional Gastrointestinal Pain and Gastroparesis

  • Baharak Moshiree
  • Renee McDonald
  • Wei Hou
  • Phillip P. Toskes
Original Article

Abstract

Background

Current pharmacologic treatments for gastroparesis have been disappointing due to the limited options available. Erythromycin ethylsuccinate is a potent prokinetic agent that stimulates gastric emptying. Recently, erythromycin has been linked to the occurrences of sudden cardiac death due to QT prolongation. Azithromycin is similar to erythromycin in structure but does not have significant drug–drug interactions as seen with erythromycin.

Purpose

This study aims to determine whether azithromycin stimulates antral activity in patients with chronic gastrointestinal pain and refractory gastroparesis.

Methods

Small bowel manometric data on 30 patients undergoing clinical evaluation for chronic digestive problems or documented refractory gastroparesis were reviewed. Antral activity was measured after infusion of erythromycin 250 mg intravenous and azithromycin (500 or 250 mg intravenous) given at different intervals during the small bowel manometry. The parameters measured included the total duration of effect, mean amplitude of antral contractions, duration of the highest antral contraction phase, number of cycles per minute, and the motility index.

Results

Comparison of erythromycin and azithromycin at similar doses showed a similar positive effect on antral activity. However, comparison of erythromycin and azithromycin at the higher dose of 500 mg showed that the mean amplitude, duration of antral activity, and motility index were significantly increased with azithromycin (P < 0.05).

Conclusions

Azithromycin stimulates antral activity similar to erythromycin and moreover has a longer duration of effect. However, unlike erythromycin, azithromycin does not have significant drug–drug interactions and may be a potential new medication for the treatment of gastroparesis and gastrointestinal dysmotility.

Keywords

Gastroparesis Gastrointestinal dysmotility Functional gastrointestinal pain Antroduodenal manometry Erythromycin Azithromycin 

References

  1. 1.
    Soykan I, Sivri B, Sarosiek I, Kiernan B, McCallum RW. Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis. Dig Dis Sci. 1998;43:2398–2404.CrossRefPubMedGoogle Scholar
  2. 2.
    Frank L, Kleinman L, Ganoczy D, et al. Upper gastrointestinal symptoms in North America. Prevalence and relationship to healthcare utilization and quality of life. Dig Dis Sci. 2000;45:809–818.CrossRefPubMedGoogle Scholar
  3. 3.
    Talley NJ, Locke GR, Lahr BD, et al. Functional dyspepsia, delayed gastric emptying, and impaired quality of life. Gut. 2006;55:933–939.CrossRefPubMedGoogle Scholar
  4. 4.
    Joshi P, Toskes PP. Clinical approach to chronic pancreatitis. J Clin Outcomes Manage. 2005;12(8):419–428.Google Scholar
  5. 5.
    Malagelada Jr, Stanghellini V. Manometric evaluation of functional upper gut symptoms. Gastroentererology. 1985;88(5 Pt 1):1223–1231.Google Scholar
  6. 6.
    Camilleri M, Brown ML, Malagelada JR. Relationship between impaired gastric emptying and abnormal gastrointestinal motility. Gastroenterology. 1986;91:94–99.PubMedGoogle Scholar
  7. 7.
    Jones KL, Berry M, Kong MF, Kwiatek MA, Samson M, Horowitz M. Hyperglycemia attenuates the gastrokinetic effect of erythromycin and affects the perception of postprandial hunger in normal subjects. Diabetes Care. 1999;22(2):339–344.CrossRefPubMedGoogle Scholar
  8. 8.
    Janssens J, Peeters TL, Vantrappen G, et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. N Engl J Med. 1990;322:1028–1031.PubMedGoogle Scholar
  9. 9.
    Hasler WL, Heldsinger A, Chung OY. Erythromycin contracts rabbit colon myocytes via occupation of motilin receptors. Am J Physiol. 1992;262(1 Pt 1):G50–G55.PubMedGoogle Scholar
  10. 10.
    Tack J, Janssens J, Vantrappen G, et al. Effect of erythromycin on gastric motility in controls and diabetic gastroparesis. Gastroenterology. 1992;103(1):72–79.PubMedGoogle Scholar
  11. 11.
    Sarna SK, Soergel KH, Koch TR, et al. Gastrointestinal motor effects of erythromycin in humans. Gastroenterology. 1991;101:1488–1496.PubMedGoogle Scholar
  12. 12.
    Otterson MF, Sarna SK. Gastrointestinal motor effects of erythromycin. Am J Physiol. 1990;259:G355–G363.PubMedGoogle Scholar
  13. 13.
    Tomomasa T, Karoumi T, Arai H, Wakabayashi K, Itoh Z. Erythromycin induces migrating motor complex in human gastrointestinal tract. Dig Dis Sci. 1986;31:157–161.CrossRefPubMedGoogle Scholar
  14. 14.
    Itoh Z, Nakaya M, Suzuki T, Arai H, Wakabayashi K. Erythromycin mimics exogenous motilin in gastrointestinal tract activity in the dog. Am J Physiol. 1984;247:G688–G694.PubMedGoogle Scholar
  15. 15.
    Annese V, Janssens J, Vantrappen G, et al. Erythromycin accelerates gastric emptying by inducing antral contractions and improved gastroduodenal coordination. Gastroenterology. 1992;102:823–828.PubMedGoogle Scholar
  16. 16.
    Strum A, Holtmann G, Goebell H, Gerken G. Prokinetics in patients with gastroparesis: a systematic analysis. Digestion. 1999;60:422–427.CrossRefGoogle Scholar
  17. 17.
    Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med. 2004;351:1089–1096.CrossRefPubMedGoogle Scholar
  18. 18.
    Wisialowski T, Crimin K, Engtrakul J, O’Donnell J, Fermini B, Fossa AA. Differentiation of the antibacterials moxifloxacin, erythromycin and telithromycin based on analysis of monophasic action potential duration alternans and cardiac instability. J Pharmacol Exp Ther. 2006;318(1):352–359.CrossRefPubMedGoogle Scholar
  19. 19.
    Milberg P, Eckardt L, Bruns HJ, Biertz J, Ramtin S, Reinsch N, Fleischer D, Kirchhof, Fabritz L, Breithardt G, Haverkamp W. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. J Pharmacol Exp Ther. 2002; 303(1): 218–225.Google Scholar
  20. 20.
    Hopkins S. Clinical toleration and safety of azithromycin. Am J Med. 1991;91(3A):40S–45S.CrossRefPubMedGoogle Scholar
  21. 21.
    Sifrim D, Matsuo H, Janssens J, Vantrappen G. Comparison of the effects of midecamycin acetate and azithromycin on gastrointestinal motility in man. Drugs Exp Clin Res. 1994;20(3):121–126.PubMedGoogle Scholar
  22. 22.
    Florescu DF, Murphy PJ, Kalil AC. Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis. Pulm Pharmacol Ther. 2009 Mar 27 [Epub ahead of print].Google Scholar
  23. 23.
    Sutera L, Dominguez LJ, Belvedere M, et al. Azithromycin in an older woman with diabetic gastroparesis. Am J Ther. 2008;15(1):85–88.CrossRefPubMedGoogle Scholar
  24. 24.
    Parkman HP, Trate DM, Knight LC, Brown KL, Maurer AH, Fisher RS. Cholinergic effects on human gastric motility. Gut. 1999;45:346–354.PubMedCrossRefGoogle Scholar
  25. 25.
    Camilleri M, Malagelada JR, Brown ML, Becker G, Zinsmeister AR. Relation between antral motility and gastric emptying of solids and liquids in humans. Am J Physiol. 1985;249(5.1):G580–G585.PubMedGoogle Scholar
  26. 26.
    Camilleri M, Malagelada JR. Abnormal intestinal motility in diabetics with gastroparesis syndrome. Eur J Clin Invest. 1984;14(6):420–427.CrossRefPubMedGoogle Scholar
  27. 27.
    Thumshirn M, Bruninga K, Camilleri M. Simplifying the evaluation of postprandial antral motor function in patients with suspected gastroparesis. Am J Gastroenterol. 1997;92(9):1496–1500.PubMedGoogle Scholar
  28. 28.
    Borotolotti M, Annese V, Coccia G. Twenty-four hour ambulatory antroduodenal manometry in normal subjects (co-operative study). Neurogastroenterol Motil. 2000;12:231–238.CrossRefGoogle Scholar
  29. 29.
    Code CF, Marlett JA. The interdigestive myo-electric complex of the stomach and small bowel of dogs. J Physiol. 1975;246(2):289–309.PubMedGoogle Scholar
  30. 30.
    Holland R, Gallagher MD, Quigly EM. An evaluation of an ambulatory manometry system in assessment of antroduodenal motor activity. Dig Dis Sci. 1996;41:1531–1537.CrossRefPubMedGoogle Scholar
  31. 31.
    Malagelada JR, Rees WD, Mazzotta LJ, Go VL. Gastric motor abnormalities in diabetic and postvagotomy gastroparesis: effect of metoclopramide and bethanechol. Gastroenterology. 1980;78(2):286–293.PubMedGoogle Scholar
  32. 32.
    Devasia RA, Jones TF, Collier B, Schaffner W. Compliance with azithromycin versus erythromycin in the setting of a pertussis outbreak. Am J Med Sci. 2009;337(3):176–178.CrossRefPubMedGoogle Scholar
  33. 33.
    Huang BH, Wu CH, Hsia CP, Yin Chen C. Azithromycin-induced torsade de pointes. Pacing Clin Electrophysiol. 2007;30(12):1579–1582.PubMedGoogle Scholar
  34. 34.
    Kezerashvili A, Khattak H, Barsky A, Nazari R, Fisher JD. Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other precipitating factors. J Interv Card Electrophysiol. 2007;18(3):243–246.CrossRefPubMedGoogle Scholar
  35. 35.
    Grayston JT, Kronmal RA, Jackson LA, et al. ACES investigators. Azithromycin for the secondary prevention of coronary events. N Engl J Med. 2005;352(16):1637–1645.CrossRefPubMedGoogle Scholar
  36. 36.
    Rubinstein E. Comparative safety of the different macrolides. Int J Antimicrob Agents. 2001;18(suppl 1):S71–S76.CrossRefPubMedGoogle Scholar
  37. 37.
    Bologna SD, Hasler WL, Owyang C. Down-regulation of motilin receptors on rabbit colon myocytes by chronic oral erythromycin. J Pharmacol Exp Ther. 1993;226(2):852–856.Google Scholar
  38. 38.
    Depoortere I, Peeters TL, Vantrappen G. Effect of erythromycin and of octreotide on motilin receptor density in the rabbit. Regul Pept. 1991;32(2):85–94.CrossRefPubMedGoogle Scholar
  39. 39.
    Talley NJ, Verlinden M, Snape W, et al. Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with, without delayed gastric emptying: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther. 2000;14(12):1653–1661.CrossRefPubMedGoogle Scholar
  40. 40.
    Depoortere I, Peeters TL, Matthijs G, Cachet T, Hoogmartens J, Vantrappen G. Structure-activity relation of erythromycin related macrolides in inducing contractions and displacing bound motilin in rabbit duodenum. J Gastrointest Motil. 1989;1:150–159.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Baharak Moshiree
    • 1
  • Renee McDonald
    • 1
  • Wei Hou
    • 2
  • Phillip P. Toskes
    • 1
  1. 1.Division of Gastroenterology, Hepatology and NutritionUniversity of FloridaGainesvilleUSA
  2. 2.Division of Biostatistics, Department of Epidemiology and Health Policy ResearchUniversity of FloridaGainesvilleUSA

Personalised recommendations